Avidity Biosciences, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To adopt (i) the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Novartis"), Ajax Acquisition Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis, and Avidity Biosciences, Inc., a Delaware corporation (the "Company"), and (ii) the Separation and Distribution Agreement, dated as of October 25, 2025 (the "Separation Agreement"), among the Company, Bryce Therapeutics, Inc., a newly formed Delaware corporation and wholly owned subsidiary of the Company, and which on December 8, 2025, changed its name to Atrium Therapeutics, Inc., and Novartis (with respect to certain sections therein).

Avidity Biosciences, Inc.’s own tally for this item (“1. The Transactions Proposal To adopt (i) the Agreement and Plan of Merger, dated as of October 25, 2025 (the " Merger Agreement "), among Novartis AG, a company limited by shares ( Aktiengesellschaft ) incorporated unde”): 123,351,048 for, 8,090 against — passed, per its Form 8-K filed February 26, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 1: The Transactions Proposal To adopt (i) the Agreement and Plan of Merger, dated as of October 25, 2025 (the " Merger Agreement "), among Novartis AG, a company limited by shares ( Aktiengesellschaft ) incorporated under the laws of Switzerland (" Novartis " or " Parent "), Ajax Acquisiti…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 32,565,486 for, 108 not voted.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Description as filed by funds: To adjourn the Special Meeting, if necessary, desirable or appropriate or to solicit additional proxies if, at the time of the Special Meeting, there are an insufficient number of votes in favor of adopting the Merger Agreement and the Separation Agreement.

The 66 asset managers below reported 30,921,141 for, 1,635,907 against, 8,042 abstained, 108 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to our named executive officers in connection with the transactions contemplated by the Merger Agreement and the Separation Agreement.

Avidity Biosciences, Inc.’s own tally for this item (“3. The Non-Binding Merger-Related Compensation Proposal To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to the Company's named executive officers in connection with the t”): 101,383,553 for, 21,654,186 against — passed, per its Form 8-K filed February 26, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The following advisory votes were cast at the Special Meeting (in person or by proxy) and the Non-Binding Merger-Related Compensation Proposal was approved:”
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 66 managers: 25,549,787 for, 7,074,016 against, 8,042 abstained, 108 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 222 managers: 74,029,527 for, 14,918,088 against, 166,332 abstained, 5,021 not voted. Showing the 25 largest; see all in the interactive database.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 1 managers: 66,864 for.

Institutional-manager reports, all 3 managers: 2,294,713 for.